Scholarlink

<p>We tested whether platelet microRNAs (miRs) expression can predict bleeding in patients supported with the HeartMate3 (HM3) left ventricular assist device (LVAD). The levels of expression of platelet miR-126, miR-233, miR-151a, and miR-454 were prospectively measured in 12 consecutive patients pre-implant and during long-term follow-up and compared based on aspirin (ASA) or ASA-free therapy at discharge and bleeding events over the course of HM3 support. Median time of follow-up was 760 (574–844) days. Seven (58%) patients were discharged on ASA and 5 (42%) without ASA. Three (25%) patients experienced 10 bleeding episodes: one never received ASA, and two suffered from bleeding recurrency long after permanent ASA discontinuation. ASA had minimal influence on platelet miRs expression. The expression levels of platelet miR-454 were lower in bleeders <i>vs.</i> non-bleeders, both pre-implant and post-implant. This study suggests the existence of a patient-specific pro-hemorrhagic phenotype associated with a distinctive expression profile of platelet miR-454. Clinical Trial Registration: <a href="https://clinicaltrials.gov/ct2/show/NCT03255928">https://clinicaltrials.gov/ct2/show/NCT03255928</a>. ClinicalTrials.gov Identifier: NCT03255928.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Platelet microRNA Expression Can Predict Bleeding in HeartMate3 Patients Treated With or Without Aspirin

  • 期刊论文

  • 发表日期：

    2025年7月11日

查看全文
  • Chiara Foglieni,
  • Davide Ravanelli,
  • Maria Lombardi,
  • Lucia Spartano,
  • Marina Pieri,
  • Silvia Ajello,
  • Giovanni Landoni,
  • Anna Mara Scandroglio,
  • Filippo Consolo

摘要

We tested whether platelet microRNAs (miRs) expression can predict bleeding in patients supported with the HeartMate3 (HM3) left ventricular assist device (LVAD). The levels of expression of platelet miR-126, miR-233, miR-151a, and miR-454 were prospectively measured in 12 consecutive patients pre-implant and during long-term follow-up and compared based on aspirin (ASA) or ASA-free therapy at discharge and bleeding events over the course of HM3 support. Median time of follow-up was 760 (574–844) days. Seven (58%) patients were discharged on ASA and 5 (42%) without ASA. Three (25%) patients experienced 10 bleeding episodes: one never received ASA, and two suffered from bleeding recurrency long after permanent ASA discontinuation. ASA had minimal influence on platelet miRs expression. The expression levels of platelet miR-454 were lower in bleeders vs. non-bleeders, both pre-implant and post-implant. This study suggests the existence of a patient-specific pro-hemorrhagic phenotype associated with a distinctive expression profile of platelet miR-454. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03255928. ClinicalTrials.gov Identifier: NCT03255928.

Graphical Abstract